巨子 ICON - 財經股票資訊及專家分析
快訊
資訊
    虛擬市場
    搜尋 股票/指數/編號

    快訊

    資訊

    ALX Oncology Holdings

    ALXO
    9.920
    0.470
    4.97%
    最少15分鐘延遲,股票資訊由第三方資訊供應商提供
    ・ALX Oncology Holdings - 延遲價格・最後更新於 28/09 8:34
    最高位
    10.140
    最低位
    9.800
    開市價
    --
    前收市價
    9.450
    成交量(千)
    4.08
    成交額(百萬)
    0.39
    買入
    7.880
    賣出
    15.900
    每手股數
    --
    市值(百萬)
    404.21
    市盈率
    --
    息率
    --
    差價
    --
    52週高低
    76.855 - 5.820
    所有資料不保證絕對正確、完整、或實時,僅作為參考使用。投資涉及風險,過往業績並不代表將來表現,作任何投資決定或交易前,閣下應諮詢獨立專業意見。所有內容均不構成投資建議。

    企業資料

    公司名稱
    ALX Oncology Holdings
    證券代碼
    ALXO.US
    所屬板塊
    Biotechnology
    公司業務
    ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.
    發行量
    40680947
    公司總部
    323 Allerton Avenue
    公司網址
    https://www.alxoncology.com
    公司電話
    +1 650 466-7125
    暫無內容

    關於

    ALX Oncology Holdings(ALXO.US)所屬的行業板塊為Biotechnology。
    ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.
    詳細公司背景可參考: https://www.alxoncology.com